CARDIFF ONCOLOGY INC (CRDF) Fundamental Analysis & Valuation

NASDAQ:CRDF • US14147L1089

Current stock price

1.8 USD
-0.02 (-1.1%)
At close:
1.8 USD
0 (0%)
After Hours:

This CRDF fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CRDF Profitability Analysis

1.1 Basic Checks

  • In the past year CRDF has reported negative net income.
  • CRDF had a negative operating cash flow in the past year.
  • CRDF had negative earnings in each of the past 5 years.
  • CRDF had a negative operating cash flow in each of the past 5 years.
CRDF Yearly Net Income VS EBIT VS OCF VS FCFCRDF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -74.13%, CRDF is doing worse than 64.41% of the companies in the same industry.
  • The Return On Equity of CRDF (-101.08%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -74.13%
ROE -101.08%
ROIC N/A
ROA(3y)-57.23%
ROA(5y)-44.79%
ROE(3y)-71.78%
ROE(5y)-54.39%
ROIC(3y)N/A
ROIC(5y)N/A
CRDF Yearly ROA, ROE, ROICCRDF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300

1.3 Margins

  • CRDF does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRDF Yearly Profit, Operating, Gross MarginsCRDF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. CRDF Health Analysis

2.1 Basic Checks

  • CRDF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CRDF has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CRDF has been increased compared to 5 years ago.
  • There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRDF Yearly Shares OutstandingCRDF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M
CRDF Yearly Total Debt VS Total AssetsCRDF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

2.2 Solvency

  • CRDF has an Altman-Z score of -6.96. This is a bad value and indicates that CRDF is not financially healthy and even has some risk of bankruptcy.
  • CRDF has a Altman-Z score of -6.96. This is in the lower half of the industry: CRDF underperforms 67.12% of its industry peers.
  • There is no outstanding debt for CRDF. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.96
ROIC/WACCN/A
WACC9.03%
CRDF Yearly LT Debt VS Equity VS FCFCRDF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.67 indicates that CRDF has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.67, CRDF perfoms like the industry average, outperforming 44.10% of the companies in the same industry.
  • CRDF has a Quick Ratio of 3.67. This indicates that CRDF is financially healthy and has no problem in meeting its short term obligations.
  • CRDF has a Quick ratio (3.67) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.67
Quick Ratio 3.67
CRDF Yearly Current Assets VS Current LiabilitesCRDF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CRDF Growth Analysis

3.1 Past

  • CRDF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 27.37%, which is quite impressive.
  • CRDF shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.30%.
  • Measured over the past years, CRDF shows a quite strong growth in Revenue. The Revenue has been growing by 9.89% on average per year.
EPS 1Y (TTM)27.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
Revenue 1Y (TTM)-13.3%
Revenue growth 3Y14.99%
Revenue growth 5Y9.89%
Sales Q2Q%60.93%

3.2 Future

  • Based on estimates for the next years, CRDF will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.48% on average per year.
  • Based on estimates for the next years, CRDF will show a very strong growth in Revenue. The Revenue will grow by 274.72% on average per year.
EPS Next Y12.83%
EPS Next 2Y-7.21%
EPS Next 3Y-18.63%
EPS Next 5Y13.48%
Revenue Next Year-9.6%
Revenue Next 2Y-31.31%
Revenue Next 3Y-44.06%
Revenue Next 5Y274.72%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CRDF Yearly Revenue VS EstimatesCRDF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B
CRDF Yearly EPS VS EstimatesCRDF Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

0

4. CRDF Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CRDF. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRDF. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRDF Price Earnings VS Forward Price EarningsCRDF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRDF Per share dataCRDF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

4.3 Compensation for Growth

  • CRDF's earnings are expected to decrease with -18.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-7.21%
EPS Next 3Y-18.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CRDF Dividend Analysis

5.1 Amount

  • No dividends for CRDF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CRDF Fundamentals: All Metrics, Ratios and Statistics

CARDIFF ONCOLOGY INC

NASDAQ:CRDF (3/20/2026, 8:00:01 PM)

After market: 1.8 0 (0%)

1.8

-0.02 (-1.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners37.33%
Inst Owner Change3.73%
Ins Owners2.27%
Ins Owner Change0%
Market Cap123.05M
Revenue(TTM)593.00K
Net Income(TTM)-45.88M
Analysts81.43
Price Target10.58 (487.78%)
Short Float %27.5%
Short Ratio14.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.59%
Min EPS beat(2)18.55%
Max EPS beat(2)42.64%
EPS beat(4)2
Avg EPS beat(4)12.25%
Min EPS beat(4)-6.95%
Max EPS beat(4)42.64%
EPS beat(8)5
Avg EPS beat(8)9.85%
EPS beat(12)8
Avg EPS beat(12)10.5%
EPS beat(16)11
Avg EPS beat(16)10.55%
Revenue beat(2)2
Avg Revenue beat(2)70.45%
Min Revenue beat(2)10.73%
Max Revenue beat(2)130.18%
Revenue beat(4)4
Avg Revenue beat(4)40.84%
Min Revenue beat(4)10.73%
Max Revenue beat(4)130.18%
Revenue beat(8)8
Avg Revenue beat(8)95.03%
Revenue beat(12)12
Avg Revenue beat(12)116.89%
Revenue beat(16)16
Avg Revenue beat(16)99.23%
PT rev (1m)-2.52%
PT rev (3m)-0.4%
EPS NQ rev (1m)25.41%
EPS NQ rev (3m)25.41%
EPS NY rev (1m)22.92%
EPS NY rev (3m)21.64%
Revenue NQ rev (1m)6.25%
Revenue NQ rev (3m)6.25%
Revenue NY rev (1m)24.25%
Revenue NY rev (3m)27.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 207.5
P/FCF N/A
P/OCF N/A
P/B 2.71
P/tB 2.71
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.01
BVpS0.66
TBVpS0.66
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.13%
ROE -101.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-57.23%
ROA(5y)-44.79%
ROE(3y)-71.78%
ROE(5y)-54.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.09%
Cap/Sales 7.42%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.67
Quick Ratio 3.67
Altman-Z -6.96
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)59.37%
Cap/Depr(5y)129.12%
Cap/Sales(3y)46.13%
Cap/Sales(5y)91.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.37%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%50%
EPS Next Y12.83%
EPS Next 2Y-7.21%
EPS Next 3Y-18.63%
EPS Next 5Y13.48%
Revenue 1Y (TTM)-13.3%
Revenue growth 3Y14.99%
Revenue growth 5Y9.89%
Sales Q2Q%60.93%
Revenue Next Year-9.6%
Revenue Next 2Y-31.31%
Revenue Next 3Y-44.06%
Revenue Next 5Y274.72%
EBIT growth 1Y1.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-0.61%
OCF growth 3YN/A
OCF growth 5YN/A

CARDIFF ONCOLOGY INC / CRDF Fundamental Analysis FAQ

What is the fundamental rating for CRDF stock?

ChartMill assigns a fundamental rating of 3 / 10 to CRDF.


What is the valuation status of CARDIFF ONCOLOGY INC (CRDF) stock?

ChartMill assigns a valuation rating of 0 / 10 to CARDIFF ONCOLOGY INC (CRDF). This can be considered as Overvalued.


How profitable is CARDIFF ONCOLOGY INC (CRDF) stock?

CARDIFF ONCOLOGY INC (CRDF) has a profitability rating of 0 / 10.


What is the expected EPS growth for CARDIFF ONCOLOGY INC (CRDF) stock?

The Earnings per Share (EPS) of CARDIFF ONCOLOGY INC (CRDF) is expected to grow by 12.83% in the next year.